Home > Oncology > ASCO GI 2023 > Pancreatic Cancer > Novel approach delivers quality-of-life benefits for patients with pancreatic cancer

Novel approach delivers quality-of-life benefits for patients with pancreatic cancer

Presented by
Dr Yaacov Lawrence, Sheba Medical Center, Israel
Conference
ASCO GI 2023
Doi
https://doi.org/10.55788/7a32cbd9

Celiac plexus radiosurgery reduced pain and the use of opioids in patients with pancreatic cancer or other tumours that involved the celiac axis. Furthermore, the health-related quality-of-life (HR-QoL) of patients appeared to be improved following this therapy. These were the main results of an international phase 2 study investigating a novel therapy that aimed to target pancreatic pain.

“At Sheba Medical Center, we developed a novel technique to target pain from pancreatic cancer, involving the administration of a very high dose of radiation, not to the tumour but to the celiac plexus (25 Gy * 1),” explained Dr Yaacov Lawrence (Sheba Medical Center, Israel). A pilot trial delivered encouraging response rates for this approach [1], instigating the current, international, phase 2 study. Dr Lawrence and co-investigators included 149 patients with retroperitoneal pain from pancreatic cancer or any other cancer involving the celiac blood vessels [2]. A previous publication reported that the primary endpoint, change in Brief Pain Inventory ‘average pain’, was met [3]. Dr Lawrence presented the HR-QoL results of the study.

The Functional Assessment of Cancer Therapy – General (FACT-G) was significantly improved from baseline to 3 and 6 weeks after therapy (mean score 57 vs 63 vs 67; P<0.05). A similar result was observed for the FACT-Hep questionnaire (mean score 96 vs 107 vs 113; P<0.05), the hepatobiliary cancer subscale (P<0.05), and the FACT-Hep trial outcome index (P<0.05). Data from FACT-G subscales demonstrated that improvements were made on the physical well-being subscale (P<0.05) and the emotional well-being subscale (P<0.05) but not on the social/family and functional well-being subscales.

These results warrant further investigation of this promising approach for the pancreatic cancer population, with a treatment showing improved HR-QoL.

  1. Hammer L, et al. Int J Radiat Oncol Biol Phys. 2022;113(3):588–593.
  2. Lawrence YR, et al. Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes. Abstract 662, ASCO-GI 2023, San Francisco, CA, USA, 19-21 January.
  3. Lawrence YR, et al. Int J Radiat Oncol Biol Phys. 2022;114(5):1060–1061.

Copyright ©2023 Medicom Medical Publishers



Posted on